Medicare reimbursement cuts reducing physician practice profitability and ability to pay MOB rents
Shift to outpatient/home-based care reducing demand for traditional medical office space
Biotech funding cycles creating boom-bust demand for lab space, particularly if IPO/M&A markets remain closed
Oversupply risk in lab markets as competitors (Alexandria, BioMed) develop competing projects in same clusters
Alexandria Real Estate (ARE) dominates lab/life science with larger scale, better locations, and deeper tenant relationships
Welltower and Ventas compete directly in MOB and senior housing with similar or larger portfolios
Private equity capital competing for healthcare real estate acquisitions, compressing cap rates and returns
Debt/Equity of 1.39x and moderate leverage (estimated 5.5-6.5x Net Debt/EBITDA) limits financial flexibility in downturn
Development pipeline concentration risk if multiple projects deliver into weak leasing environment
Floating-rate debt exposure (~$500M-1B estimated) creates earnings volatility as SOFR fluctuates
StructuralCompetitiveBalance Sheet